Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atsushi Satake

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Annals of Hematology|July 6, 2026
Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective studyTaichiro Tokura, Satoshi Wakita, Keiko Fukunaga, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Annals of Hematology|July 6, 2026
Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective studyTaichiro Tokura, Satoshi Wakita, Keiko Fukunaga, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 9